Clinical variables associated with the isolation of Klebsiella pneumoniae expressing different extended-spectrum β-lactamases

Clinical Microbiology and Infection

Volumn 13, Issue 5, 2007, Pages 532-538

  Garcia San Miguel L ^a   Cobo, J ^a   Valverde, A ^a   Coque, T M ^a   Diz, S ^a   Grill, F ^a   Canton R ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Bacteraemia; Catheter related infections; Clinical variables; Extended spectrum lactamases; Klebsiella pneumoniae; Urinary tract infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; BETA LACTAMASE CTX M 10; BETA LACTAMASE CTX M 14; BETA LACTAMASE CTX M 15; BETA LACTAMASE CTX M 9; BETA LACTAMASE SHV; BETA LACTAMASE TEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DRUG USE; ENTEROBACTER INFECTION; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINARY TRACT INFECTION; URINE CATHETER; WARD;

KLEBSIELLA PNEUMONIAE;

EID: 34147160322     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01685.x     Document Type: Article

References (39)

1. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-686.
2. Bonnet R. Growing group of extended-spectrum β-lactamases: The CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
3. Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006; 9: 466-475.
4. Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
5. Brigante G, Luzzaro F, Perilli M et al. Evolution of CTX-M-type β-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents 2005; 25: 157-162.
6. Valverde A, Coque TM, Sánchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-4775.
7. Romero L, López L, Rodríguez-Baño J, Hernández JR, Martínez-Martínez L, Pascual A. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases. Clin Microbiol Infect 2005; 11: 625-631.
8. Gniadkowski M. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7: 597-608.
9. Graffunder EM, Preston KE, Evans AM et al. Risk factors associated with extended-spectrum β-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 2005; 56: 139-145.
10. Pitout JD, Nordmann P, Laupland KB et al. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.
11. Gupta A, Ampofo K, Rubenstein D et al. Extended spectrum β-lactamase-producing Klebsiella pneumoniae infections: A review of the literature. J Perinatol 2003; 23: 439-443.
12. Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 63-67.
13. Hernández JR, Pascual A, Cantón R et al. Escherichia coli y Klebsiella pneumoniae productores de ß-lactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21: 77-82.
14. Cantón R, Coque TM, Baquero F. Multi-resistant gram-negative bacilli: From epidemics to endemics. Curr Opin Infect Dis 2003; 16: 315-325.
15. Machado E, Cantón R, Baquero F et al. Integron content of extended-spectrum β-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain. Antimicrob Agents Chemother 2005; 49: 1823-1829.
16. Coque TM, Oliver A, Pérez-Díaz JC et al. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum β-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989-2000). Antimicrob Agents Chemother 2002; 46: 500-510.
17. Paterson DL, Ko WC, Von Gottberg A et al. International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.
18. Mendelson G, Hait V, Ben-Israel J et al. Prevalence and risk factors of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis 2005; 24: 17-22.
19. Du B, Long Y, Liu H et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: Risk factors and clinical outcome. Intens Care Med 2002; 28: 1718-1723.
20. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-4581.
21. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: Epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-1491.
22. Rodriguez-Baño J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42: 37-45.
23. Pitout JD, Hanson ND, Church DL et al. Population-based laboratory surveillance for Escherichia coli producing extended-spectrum β-lactamases: Importance of community isolates with bla CTX-M genes. Clin Infect Dis 2004; 38: 1736-1741.
24. Jarlier V, Nicolas MH, Fournier G et al. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
25. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing, 15th informational supplement. M100-S15. Wayne, PA: CLSI, 2005.
26. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16: 128-140.
27. Asensio A, Oliver A, Gonzalez-Diego P et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin Infect Dis 2000; 30: 55-60.
28. Paterson DL, Hujer KM, Hujer AM et al. International Klebsiella Study Group. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: Dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47: 3554-3560.
29. Zaoutis TE, Goyal M, Chu JH et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115: 942-949.
30. Pessoa-Silva CL, Meurer Moreira B, Camara Almeida V et al. Extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit: Risk factors for infection and colonization. J Hosp Infect 2003; 53: 198-206.
31. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-463.
32. Kang CI, Kim SH, Kim DM et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25: 860-867.
33. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum β-lactamase Klebsiella pneumoniae: A case-control study in a district teaching hospital in Taiwan. J Hosp Infect 2003; 53: 39-45.
34. Lautenbach E, Patel JB, Bilker WB et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-1171.
35. Guillemot D, Bonacorsi S, Blanchard JS et al. Amoxicillin-clavulanate therapy increases childhood nasal colonization by methicillin-susceptible Staphylococcus aureus strains producing high levels of penicillinase. Antimicrob Agents Chemother 2004; 48: 4618-4623.
36. Mohammedi I, Ploin D, Duperret S et al. Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: A clinical study. Intens Care Med 2003; 29: 1164-1168.
37. Leflon-Guibout V, Ternat G, Heym B et al. Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother 2002; 49: 367-371.
38. Piroth L, Aube H, Doise JM et al. Spread of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Are β-lactamase inhibitors of therapeutic value? Clin Infect Dis 1998; 27: 76-80.
39. Oliver A, Pérez-Díaz JC, Coque TM, Baquero F, Cantón R. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing β-lactamase (CTX-M-10) isolated in Spain. Antimicrob Agents Chemother 2001; 45: 616-620.